Classical immunomodulatory therapy in multiple sclerosis: How it acts, how it works;Terapêutica imunomoduladora clássica na esclerose múltipla: Como atua, como funciona

Arquivos de Neuro-Psiquiatria

Volumn 69, Issue 3, 2011, Pages 536-543

  Mendes, Amélia ^a   Sá, José Maria ^a,b  

^a HOSPITAL DE SÃO JOÃO   (Portugal)

^b UNIVERSIDADE FERNANDO PESSOA   (Portugal)

Author keywords

Glatiramer acetate; Immunomodulatory therapy; Interferon beta; Multiple sclerosis

Indexed keywords

5' NUCLEOTIDASE; B7 ANTIGEN; BETA INTERFERON; BETA1A INTERFERON; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; CD4 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; GELATINASE B; GLATIRAMER; INTERFERON BETA SERINE; INTERFERON RECEPTOR; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; NEUTRALIZING ANTIBODY; RANTES; SERUM ALBUMIN; TOLL LIKE RECEPTOR 7; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4;

ALLERGIC REACTION; ANTIGEN PRESENTATION; ANTIVIRAL ACTIVITY; B LYMPHOCYTE; BLOOD BRAIN BARRIER; CELL ACTIVATION; CELL ACTIVITY; DEPRESSION; DRUG BINDING; DRUG POTENCY; DRUG SAFETY; FLU LIKE SYNDROME; HEMATOLOGIC FUNCTION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; INJECTION SITE REACTION; LIVER FUNCTION; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MEMBRANE PERMEABILITY; MULTIPLE SCLEROSIS; NEUROPROTECTION; PHOSPHORYLATION; REVIEW; SIDE EFFECT; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL; TH2 CELL;

EID: 79960587123     PISSN: 0004282X     EISSN: 16784227     Source Type: Journal    
DOI: 10.1590/S0004-282X2011000400024     Document Type: Review

References (59)

1. Lublin FD, Miller AE. Multiple sclerosis and other inflammatory demyelinating diseases of the central nervous system. In Bradley WG, Daroff RB, Fenichel GM, Jankovic J (Eds). Neurology in clinical practice, 5th edition, Philadelphia: Butterworth Heinemann 2008:1588-1613.
2. Ramagopalan SV, Dobson R, Meier UC, Giovannoni G. Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol 2010; 9:727-739.
3. Goodin DS. Treatment of multiple sclerosis with human beta interferon. Int MS J 2005;12:96-108.
4. Markowitz CE. Interferon-beta: mechanism of action and dosing issues. Neurology 2007;68(Suppl):8-11.
5. Rudick RA, Ransohoff RM. Biologic effects of interferons: relevance to multiple sclerosis. Mult Scler 1995;1(Suppl 1):S12-S16.
6. Dhib-Jalbut S, Marks S. Interferon beta mechanisms of action in multiple sclerosis. Neurology 2010;74(Suppl 1):17-24.
7. Jiang H, Milo R, Swoveland P, Johnson KP, Panitch H, Dhib-Jalbut S. Interferon beta-1b reduces interferon gamma-induced antigen presenting capacity of human glial and B cells. J Neuroimmunol 1995;61:17-22.
8. Yong VW, Chabot S, Stuve O, Williams G. Interferon beta in the treatment of multiple sclerosis-mechanisms of action. Neurology 1998;51:682-689.
9. Joshi S, Kaur S, Redig AJ, et al. Type I interferon (IFN)-dependent activation of Mnk1 and its role in the generation of growth inhibitory responses. Proc Natl Acad Sci USA 2009;106:12097-12102.
10. Aranami T, Yamamura T. Th17 Cells and autoimmune encephalomyelitis (EAE/MS). Allergol Int 2008;57:115-120.
11. Zhang X, Jin J, Tang Y, Speer D, Sujkowska D, Markovic-Plese S. IFN-beta1a inhibits the secretion of Th17-polarizing cytokines in human dendritic cells via TLR7 up-regulation. J Immunol 2009;182:3928-3936.
12. Sharief MK, Semra YK, Seidi OA, Zoukos Y. Interferon-beta therapy downregulates the anti-apoptosis protein FLIP in T cells from patients with multiple sclerosis. J Neuroimmunol 2001;120:199-207.
13. Iarlori C, Reale M, Lugaresi A, et al. RANTES production and expression is reduced in relapsing-remitting multiple sclerosis patients treated with interferon-beta-1b. J Neuroimmunol 2000;107:100-107.
14. Cepok S, Schreiber H, Hoffmann S, et al. Enhancement of chemokine expression by interferon beta therapy in patients with multiple sclerosis. Arch Neurol 2009;66:1216-1223.
15. Krumbholz M, Faber H, Steinmeyer F, et al. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain 2008;131:1455-1463.
16. Ozenci V, Kouwenhoven M, Teleshova N, Pashenkov M, Fredrikson S, Link H. Multiple sclerosis: pro- and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with IFNß. J Neuroimmunol 2000;108: 236-243.
17. Karabudak R, Kurne G, Guc D, Sengelen M, Canpinar H, Kansu E. Effects of IFNß-1a on serum matrix MMP-9 and tissue inhibitor of matrix metalloproteinase in relapsing-remitting multiple sclerosis patients: one year follow-up results. J Neurol 2004;251:279-283.
18. Graber J, Zhan M, Ford D, et al. IFNß-1a induces increases in vascular cell adhesion molecule: implications for its modes of action in multiple sclerosis. J Neuroimmunol 2005;161:169-176.
19. Uhm JH, Dooley NP, Stuve O, et al. Migratory behavior of lymphocytes isolated from multiple sclerosis patients: effects of interferon b-1b therapy. Ann Neurol 1999;46:319-324.
20. Huynh HK, Oger J, Dorovini-Zis K. Interferon beta downregulates interferon gamma-induced class II MHC molecule expression and morphological changes in primary cultures of human brain microvessel endothelial cells. J Neuroimmunol 1995;60:63-73.
21. Calabresi PA, Tranquill LR, Dambrosia JM, et al. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b. Ann Neurol 1997;41:669-674.
22. Mameli G, Serra C, Astone V, et al. Inhibition of multiple-sclerosis-associated retrovirus as biomarker of interferon therapy. J Neurovirol 2008;14:73-77.
23. Garcia-Montojo M, De Las Heras V, Bartolome M, Arroyo R, Alvarez-Lafuente R. Interferon beta treatment: bioavailability and antiviral activity in multiple sclerosis patients. J Neurovirol 2007;13:504-512.
24. Narayanan S, De Stefano N, Francis GS, et al. Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol 2001; 248:979-986.
25. IFN-ß Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo controlled trial. Neurology 1993;43:655-661.
26. Paty DW, Li DKB, UBC MS/MRI Study Group, IFN-beta Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo controlled trial. Neurology 1993;43:662-667.
27. Jacobs LD, Cookfair DL, Rudick RA, et al. The Multiple Sclerosis Collaborative Research Group: intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294.
28. PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001;56:1628-1636.
29. Freedman MS, Francis GS, Sanders EA, et al. Once weekly interferon beta-1alpha for Multiple Sclerosis Study Group; University of British Columbia MS/MRI Research Group. Randomized study of once-weekly interferon beta-1la therapy in relapsing multiple sclerosis: three-year data from the OWIMS study. Mult Scler 2005;11:41-45
30. European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352:1491-1497.
31. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000;343:898-904.
32. Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007;370:389-397.
33. Stürzebecher S, Maibauer R, Heuner A, Beckmann K, Aufdembrinke B. Pharmacodynamic comparison of single doses of IFN-beta1a and IFN-beta1b in healthy volunteers. J Interferon Cytokine Res 1999;19:1257-1264.
34. Goodin DS, Frohman EM, Garmany GP Jr, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technological Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002;58:169-178.
35. Durelli L, Verdun E, Barbero P, et al. Independent Comparison of Interferon (INCOMIN) Trial Study Group. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002;359:1453-1460.
36. Panitch H, Goodin DS, Francis G, et al., EVIDENCE Study Group. Evidence of Interferon Dose-response: European North American Comparattive Efficacy; University of British Columbia MS/MRI Research Group. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial. Neurology 2002;59:1496-1506.
37. Patti F, Pappalardo A, Florio C, et al. Effects of interferon beta-1a and -1b over time: 6-year results of an observational head-to-head study. Acta Neurol Scand 2006;113:241-247.
38. Sørensen PS, Deisenhammer F, Duda P, et al. EFNS Task Force on Anti-IFN-beta Antibodies in Multiple Sclerosis. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 2005;12:817-827.
39. Goodin DS, Frohman EM, Hurwitz B, et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2007; 68:977-984.
40. O'Connor P, Filippi M, Arnason B, et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 2009;8:889-897.
41. Boskovic R, Wide R, Wolpin J, Bauer DJ, Koren G. The reproductive effects of beta interferon therapy in pregnancy: a longitudinal cohort. Neurology 2005;65:807-811.
42. Racke MK, Lovett-Racke AE, Karandikar NJ. The mechanism of action of glatiramer acetate treatment in multiple sclerosis. Neurology 2010;74 (Suppl 1):25-30.
43. Schrempf W, Ziemssen T. Glatiramer acetate: mechanisms of action in multiple sclerosis. Autoimmun Rev 2007;6:469-475.
44. Neuhaus O, Farina C, Wekerle H, Hohlfeld R. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 2001; 56: 702-708
45. Schmied M, Duda PW, Krieger JI, Trollmo C, Hafler DA. In vitro evidence that subcutaneous administration of glatiramer acetate induces hyporesponsive T cells in patients with multiple sclerosis. Clin Immunol 2003;106:163-174.
46. Comi G, Moiola L. Glatiramer acetate. Neurologia 2002;17:244-258.
47. Li Q, Milo R, Panitch H, Swoveland P, Bever CT Jr. Glatiramer acetate blocks the activation of THP-1 cells by interferon?. Eur J Pharmacol 1998; 342:303-310.
48. Burger D, Molnarfi N, Weber MS, et al. Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis. Proc Natl Acad Sci U S A 2009;106:4355-4359.
49. Rizvi SA, Kim E, Moodie J. Glatiramer in the treatment of multiple sclerosis Internat J Nanomed 2006;1:283-289.
50. Khan O, Shen Y, Bao F, et al. Long-term study of brain 1H-MRS study in multiple sclerosis: effect of glatiramer acetate therapy on axonal metabolic function and feasibility of long-Term H-MRS monitoring in multiple sclerosis. J Neuroimaging 2008;18:314-319.
51. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer I reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled. The Copolymer I Multiple Sclerosis Study Group. Neurology 1995;45:1268-1276.
52. Ford CC, Johnson KP, Lisak RP, et al. The Copaxone Study Group: a prospective open-label study of glatiramer acetate:over a decade of continuous use in multiple sclerosis patients. Mult Scler 2006;12:309-320.
53. Comi G, Filippi M, Wolinsky JS, the European/Canadian GA study group. 2001. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of GA on MRI-measured activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001;49: 290-297.
54. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009;374:1503-1511.
55. Wolinsky JS, Pardo L, Stark Y et al., the PROMISE study group. Effect of GA on primary progressive MS: initial analysis of the completed PROMISE trial. Neurology 2004;62(Suppl 5):97-98.
56. Weber-Schoendorfer C, Schaefer C. Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. Mult Scler 2009;15:1037-1042.
57. Mikol DD, Barkhof F, Chang P, et al., REGARD study group. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study: a multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008;7:903-914.
58. Cadavid D, Wolansky LJ, Skurnick J, et al. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology 2009;72:1976-1983.
59. Patti F. Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence. Patient Prefer Adherence 2010;4:1-9.